Interactions of eristostatin with melanoma cells and its effects on natural killer cell cytotoxicity
| Author(s) | Mahmoud, Alaa | |
| Date Accessioned | 2010-08-06T19:20:14Z | |
| Date Available | 2010-08-06T19:20:14Z | |
| Publication Date | 2010-05 | |
| Abstract | The ability of Natural Killer (NK) cells to lyse cancerous cells has been well documented. Interestingly, it has previously been shown that 4μM eristostatin, a snake venom disintegrin from Eristocophis macmahoni, elicits a 2-fold increase in the lytic ability of TALL-104 cells, NK-like cells, towards SbCl2, a radial growth phase melanoma cell line (McLane et al., 2001). Since TALL-104 cells exhibited a 2-fold increase in lytic ability towards SbCl2, it was hypothesized that eristostatin could also enhance the lytic ability of NK cells toward other melanoma cell lines (MV3, M24met, SbCl2, C8161, WM164, and 1205Lu). The lytic ability of NK cells was enhanced at select effector: target (E:T) ratios for several cell lines after a three hour incubation. However, with C8161, it was found that eristostatin suppressed the lytic ability of NK cells. The complexity of the study did not permit a general all encompassing answer to the question of whether eristostatin enhances the lytic ability of NK cells toward melanoma cells in general. Although the aim of the study was to investigate the above mentioned question, it was found that eristostatin increased the survivability of certain melanoma cells in vitro after a three hour incubation; a finding worthy of further study. | en |
| Advisor | Mary Ann McLane | |
| Program | Medical Technology | |
| URL | http://udspace.udel.edu/handle/19716/5513 | |
| Publisher | University of Delaware | en |
| dc.subject.lcsh | Eristostatin | |
| dc.subject.lcsh | Melanoma | |
| dc.subject.lcsh | Cancer cells | |
| dc.subject.lcsh | Killer cells | |
| dc.subject.lcsh | Cell-mediated cytotoxicity | |
| Title | Interactions of eristostatin with melanoma cells and its effects on natural killer cell cytotoxicity | en |
| Type | Thesis | en |